Correlation Between Immix Biopharma and Prime Medicine,

Can any of the company-specific risk be diversified away by investing in both Immix Biopharma and Prime Medicine, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Immix Biopharma and Prime Medicine, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Immix Biopharma and Prime Medicine, Common, you can compare the effects of market volatilities on Immix Biopharma and Prime Medicine, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Immix Biopharma with a short position of Prime Medicine,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Immix Biopharma and Prime Medicine,.

Diversification Opportunities for Immix Biopharma and Prime Medicine,

-0.58

Correlation Coefficient

Immix Biopharma  Prime Medicine,

Excellent diversification

The 3 months correlation between Immix and Prime is -0.58. Overlapping area represents the amount of risk that can be diversified away by holding Immix Biopharma and Prime Medicine, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Prime Medicine, Common and Immix Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Immix Biopharma are associated (or correlated) with Prime Medicine,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Prime Medicine, Common has no effect on the direction of Immix Biopharma i.e., Immix Biopharma and Prime Medicine, go up and down completely randomly.

Pair Corralation between Immix Biopharma and Prime Medicine,

Given the investment horizon of 90 days Immix Biopharma is expected to generate 1.21 times more return on investment than Prime Medicine,. However, Immix Biopharma is 1.21 times more volatile than Prime Medicine, Common. It trades about 0.03 of its potential returns per unit of risk. Prime Medicine, Common is currently generating about -0.08 per unit of risk. If you would invest  212.00  in Immix Biopharma on September 27, 2024 and sell it today you would earn a total of  6.00  from holding Immix Biopharma or generate 2.83% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Immix Biopharma  vs.  Prime Medicine, Common

Immix Biopharma

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Immix Biopharma are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak primary indicators, Immix Biopharma showed solid returns over the last few months and may actually be approaching a breakup point.

Prime Medicine, Common

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Prime Medicine, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Etf's primary indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the fund shareholders.

Pair Trading with Immix Biopharma and Prime Medicine,

The main advantage of trading using opposite Immix Biopharma and Prime Medicine, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Immix Biopharma position performs unexpectedly, Prime Medicine, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Prime Medicine, will offset losses from the drop in Prime Medicine,'s long position.

The idea behind Immix Biopharma and Prime Medicine, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.